NZX Interim Announcement

Results for announcement to the market
For the six month reporting period to September 30 2015
(Previous six month reporting period to September 30 2014)
Amount
Percentage
NZ$’000
Change
Revenues from ordinary activities
29,543
22.3%
Loss from ordinary activities after
Tax attributable to security holders
(6,367)
(4.2%)
Net Loss attributable to security
Holders
(5,947)
0.1%
Interim/Final Dividend
Amount per security
NZ$
Imputed amount per security NZ$
Series A preference shares on record date June 30 2015 were
paid a 6% per annum dividend on July 14 2015
2.46
0.85
Series A preference shares on record date September 30 2015
were paid a 6% per annum dividend on October 15 2015
2.55
0.88
Series B preference shares on record date June 30 2015 were
paid a 5% per annum dividend on July 14 2015
1.33
0.52
Series B preference shares on record date September 30 2015
were paid a 5% per annum dividend on October 15 2015
2.43
0.95
All preference shares converted to ordinary shares on a one
for one basis immediately prior to the allotment of shares
under the Initial public offering on December 21st 2015.
Accordingly, there will be no further preference shares
dividends from this date.
Net Tangible Assets per share
September 30 2015
NZ$
September
30 2014
NZ$
Net Tangible Assets per share
1.78
6.74
Accompanying this announcement are the Group’s unaudited
consolidated interim financial statements for the six months
ended 30 September 2015. These financial statements and the
commentary within the Product Disclosure Statement dated
December 1 2015 provide the balance of information
requirements in accordance with NZX Listing Rule 10.3.2 and
Appendix 1. 151229-NZX-Interim-Announcement-3.pdf

May 1, 2024

AFT Licenses Maxigesic® IV in Brazil

We are delighted to announce our partnership with Brazil’s Halex Istar, and to be exclusively responsible for distributing its Maxigesic IV in Brazi…

Read More

April 24, 2024

AFT, Massey Ventures, Gilles McIndoe to develop scar treatment

AFT collaborate with Massey Ventures and Gilles McIndoe to begin the development of a topical treatment for keloid and hypertrophic scarring….

Read More

March 5, 2024

AFT makes further progress in international markets

AFT Pharmaceuticals provides an update on recent progress it has made in international markets….

Read More